Caribou Biosciences picks up $115m Series C

Caribou Biosciences Inc, a CRISPR genome editing biotechnology company, has secured $115 million in Series C financing.

Caribou Biosciences Inc, a CRISPR genome editing biotechnology company, has secured $115 million in Series C financing. Farallon Capital Management, PFM Health Sciences, and Ridgeback Capital Investments led the round.

Source: Press Release